Brain Disease Device and Software Market Report 2025

The brain disease device and software market size has grown rapidly in recent years. It will grow from $14.11 billion in 2024 to $15.59 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, increasing awareness of early diagnosis and treatment for brain diseases, growing demand for non-invasive diagnostic tools, expanding government investments in healthcare infrastructure, and heightened patient preference for home-based neurological monitoring.

The brain disease device and software market size is expected to see rapid growth in the next few years. It will grow to $22.94 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth during the forecast period can be attributed to the increasing demand for personalized brain disease management solutions, expanding use of cloud-based platforms for brain health data analysis, rising focus on remote patient monitoring and telehealth services, greater penetration of smartphones and mobile health apps, and growing adoption of digital therapeutics for cognitive disorders. Key trends in the forecast period include integration of wearable brain monitoring devices, advancements in neurostimulation devices, development of closed-loop neurostimulation systems, and innovations in imaging and neuroimaging technologies.

The rising prevalence of neurological disorders is expected to drive growth in the brain disease device and software market. Neurological disorders affect the brain, spinal cord, and nerves, causing cognitive, motor, and sensory impairments. Their increasing occurrence is associated with the aging global population, as aging reduces neuronal function, decreases brain plasticity, and increases oxidative stress, contributing to disease onset and progression. Brain disease devices and software aid in managing these conditions by enabling early diagnosis and continuous monitoring. Advanced AI and data analytics support timely intervention, improving patient care and treatment outcomes. For example, in July 2024, the UK’s National Health Service reported 487,432 patients diagnosed with dementia by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. Consequently, the growing prevalence of neurological disorders is fueling the brain disease device and software market.

Companies in this market are developing innovative digital healthcare solutions to improve early diagnosis and management of neurological disorders. Digital healthcare solutions utilize software, connected devices, and data analytics to support prevention, diagnosis, monitoring, and treatment of conditions such as neurological disorders. In July 2022, Linus Health Inc., a US-based digital health company, launched an iPad-based brain health platform for early detection of Alzheimer’s disease and other dementias in primary care. The platform combines digital cognitive assessments with AI-driven analytics to provide clinicians actionable insights, enabling earlier intervention and personalized care plans. It is designed to integrate seamlessly into routine primary care visits, improving accessibility and efficiency in detecting cognitive decline. This highlights the growing role of digital tools in transforming neurological care, offering scalable and precise solutions for managing brain health.

In April 2022, Blackrock Microsystems Inc., a US-based medical device company, acquired MindX Corp for an undisclosed amount. The acquisition aims to combine Blackrock’s BCI hardware with MindX’s AR and AI software to develop advanced brain-computer interface products that enhance patient independence and quality of life. MindX Corp, based in the UK, specializes in brain disease devices and software.

Major players in the brain disease device and software market are Medtronic plc, Insightec Ltd., Cadwell Industries Inc., NeuroPace Inc., Synchron Inc., Compumedics Ltd., Neuronetics Inc., BrainsWay Ltd., The Magstim Company Ltd., Paradromics Inc., Linus Health Inc., MagVenture A/S, Neurophet Inc., Neuroelectrics Corporation, BrainScope Company Inc, Blackrock Neurotech LLC, Neurable Inc., NeuroSigma Inc., Cognixion Inc., Brightmind.AI.

North America was the largest region in the brain disease device and software market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in brain disease device and software market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the brain disease device and software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Brain disease devices and software refer to specialized medical tools and digital applications designed to diagnose, monitor, and manage neurological disorders and brain-related conditions. These solutions assist in detecting abnormalities, guiding therapies, and managing diseases, with the primary goal of improving patient outcomes through accurate assessment, personalized treatment, and continuous brain health monitoring.

The main categories of brain disease devices and software are brain disease devices and brain disease software. Brain disease devices are medical tools developed to diagnose, monitor, treat, or support rehabilitation for neurological disorders affecting brain function. They leverage technologies such as wearable devices, telemedicine platforms, artificial intelligence and machine learning, mobile health applications, and neuroimaging techniques. These devices are applied in conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and other neurological disorders, serving end users including hospitals and clinics, home care settings, rehabilitation centers, research and academic institutions, and diagnostic laboratories.

The brain disease device and software market research report is one of a series of new reports that provides brain disease device and software market statistics, including brain disease device and software industry global market size, regional shares, competitors with a brain disease device and software market share, detailed brain disease device and software market segments, market trends and opportunities, and any further data you may need to thrive in the brain disease device and software industry. This brain disease device and software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain disease device and software market consists of revenues earned by entities by providing services such as brain mapping services, remote neurological consultation, neurocognitive assessment, neurofeedback therapy, and personalised rehabilitation planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The brain disease devices and software market also includes sales of brain-computer interface systems, intracranial pressure monitors, transcranial magnetic stimulation devices, virtual reality-based rehabilitation kits, and portable electroencephalography headsets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.